|
Questioning Semaglutide’s CVD Impact | iCardio Clearance
October 21, 2024
|
|
|
|
|
Together with
|
|
|
|
“GLP-1 RA are not simply ‘weight loss drugs,’ but rather are CV and kidney risk-reduction agents that fall squarely within the scope of practice of cardiologists.”
|
|
Neha J. Pagidipati MD, MPH
|
|
|
Drug-coated balloons have been a go-to option for in-stent restenosis for over a decade, but U.S. patients and physicians have historically been limited to other, often inferior, treatments. That changed with the FDA approval of Boston Scientific’s AGENT™ Drug-Coated Balloon. Learn more about the AGENT™ Drug-Coated Balloon’s proven ability to treat ISR, and its potential impact in the U.S., in this Cardiac Wire Show interview with Boston Scientific’s chief medical officer for Interventional Cardiology Therapies, Janarthanan Sathananthan, MD, FSCAI.
|
|
|
|
JACC took a deep dive into semaglutide’s cardiovascular impact, publishing six analyses of three separate trials that delivered new insights into the drug’s heart benefits, while raising even more questions about how it works.
One STEP-HFpEF trial analysis showed that patients with obesity-related HFpEF on semaglutide achieved cardiac remodeling benefits beyond the impact of weight loss.
- Semaglutide improved LA volume, LV diastolic function, and RV size, without affecting LV remodeling or LA mechanics.
- The LA volume benefits stemmed from weight loss, but improvements to LV diastolic function and RV size were due to semaglutide itself.
Another analysis of STEP-HFpEF suggested semaglutide decreases inflammation in patients with obesity-related HFpEF.
- Semaglutide decreased CRP, independent of weight loss or KCCQ-CSS and 6MWD improvements.
- While semaglutide decreased inflammation, it’s still unproven whether inflammation reduction leads to HF improvements.
The final STEP-HFpEF substudy found semaglutide to be especially effective at improving quality of life in patients with both AFib and obesity-related HFpEF.
- Semaglutide improved KCCQ-CSS scores, especially in patients with AFib.
- Reductions in CRP and weight were similar regardless of AFib status, suggesting semaglutide’s benefits in AFib/HFpEF patients go beyond inflammation and weight improvements.
Moving on to the SELECT trial, one substudy demonstrated semaglutide to be more effective in women for reducing inflammation and body mass.
- Women had greater weight loss and CRP reduction than men with semaglutide, but MACE and eGFR benefits were equal for both sexes.
- Even though weight loss and CRP reduction varied by sex, patient outcomes didn’t.
Another SELECT substudy found semaglutide significantly reduces COVID-related outcomes in patients with ASCVD and obesity.
- Semaglutide treatment reduced COVID-related mortality by 34% in people with ASCVD and obesity, while cutting serious adverse events (232 vs 277), although they couldn’t define the mechanisms of these reductions.
Finally, an analysis of the FLOW trial discovered semaglutide might both treat and prevent HF in patients with CKD and T2DM.
- Semaglutide decreased HF events and CV death by 27%, regardless of HF status, although how it did so was unclear.
The Takeaway
More than ever before, semaglutide seems like a wonder drug for weight-dependent heart conditions, but just how it works is still unclear. Even though there are plenty of drugs with unknown mechanisms of action, more research would help better define what drives semaglutide’s cardiovascular benefits.
|
|
|
Identify and Treat Cardiovascular Disease
Complex care pathways make getting patients to the next step a challenge. See how Tempus Next, an AI enabled care pathway platform, helps providers identify and reduce under treatment in cardiovascular disease by adding an intelligent layer onto their routinely generated EHR data.
|
|
Cardiology’s Path to Enterprise Imaging
By connecting healthcare teams through every image, every scan and every report, we can reveal the full picture of a patient’s story. Check out this GE HealthCare Cardiology Coffee Break and see how enterprise imaging seamlessly integrates with existing technology infrastructures, ensuring compatibility across systems and platforms, enhances workflow efficiency, and more.
|
|
- iCardio’s FDA Clearance: iCardio.ai received FDA 510(k) clearance for its echocardiography interpretation software, EchoMeasure, which leads with its comprehensive imaging workflow and autonomous preliminary reporting. With the clearance, iCardio.ai will ramp up its commercial operations, following its early integrations at several partner health systems. EchoMeasure will also be used as a foundational algorithm for the company’s forthcoming products, like its structural heart disease suite.
- COVID’s CVD Impact: UK Biobank analysis suggests that COVID’s long-term cardiovascular risks might be worse than initially thought. The risk of MACE was 2x higher in COVID patients and nearly 4x higher in patients who were hospitalized with COVID (HRs: 2.09 & 3.85), while post–acute MI and stroke risk increased the most in non-O blood type patients. Based on that, COVID hospitalization represents a coronary artery disease risk “equivalent” (like obesity or smoking), and is one of the first examples of a gene-pathogen exposure interaction for thrombotic events.
- SCAI’s New PCI Guidelines: An expert consensus statement from the SCAI outlined the standards required for cath labs performing primary PCI in STEMI patients. The statement includes guidelines on necessary tools (plaque modification, microcatheters, transvenous pacing, etc) and also lays out the appropriate reperfusion times (within 90-120 minutes depending on severity). Other highlighted recommendations include catheter access points, supersaturated oxygen, mild hypothermia, and left ventricular unloading to reduce infarct size in STEMI patients.
- EBPs Reduce Kidney Injury: Using a nonselective extracorporeal blood purification (EBP) device connected to the CPB circuit could significantly reduce cardiac surgery-associated acute kidney injury (CSA-AKI) in the first 7 days following the procedure. The SIRAKI02 trial examined 343 adults undergoing nonemergent cardiac surgery who were at high risk for CSA-AKI, half received EBP and half received standard care. CSA-AKI rates were far lower in the EBP group compared to the standard care group (28.4% vs. 39.7%).
- Contego’s Premarket Approval: Contego Medical announced FDA premarket approval of its Neuroguard IEP System, a 3-in-1 carotid stenting device that combines a high-performance stent, dilation balloon, and filter. Neuroguard reduces the number of steps in carotid stent procedures and makes them safer by capturing emboli that traditional protection systems do not. Clinical studies of the system have consistently recorded unprecedented low event rates – zero major strokes, zero neurologic deaths, and zero stent thrombosis at 30 days and 1 year.
- Sweeteners’ CAC Link: It could be time to put down that Diet Coke, as a new study found that people who drink artificially sweetened beverages had higher CAC progression on CT scans. Data from 2.5k U.S. adults who got CAC scans showed that low and high consumption of artificially sweetened beverages was associated with greater CAC progression (HR=1.35 & 1.54) compared to people who don’t consume diet drinks.
- Shorter DAPT Proves Effective: Shorter duration of dual antiplatelet therapy (DAPT) in patients with ACS undergoing PCI could be just as effective for reducing MACCE as the current 12 month guideline. A meta-analysis of 15 randomized clinical trials and 35k patients found 1-3 months of DAPT followed by potent P2Y12 inhibitor monotherapy (ticagrelor or prasugrel) was associated with a reduction in major bleeding without increasing recurrent ischemic events. The three month duration proved most effective at reducing MACCE.
- ICM Predictions: Results from the ALLEVIATE-HF trial suggest diagnostic variables from insertable cardiac monitors (ICMs) may be useful in identifying patients at increased risk of HF events. The study provided ICMs to 59 patients with a recent HF event and risk-scored them based on impedance, respiration rate, AFib burden, and heart rate activity. Researchers recorded 146 high‐risk scores in 33 patients, leading to 118 interventions in 75 of the high‐risk alerts that did not meet safety rule‐out criteria.
- McLaren Heart & Vascular Institute: McLaren Health Care established the McLaren Heart & Vascular Institute, unifying its 13 hospital-based cardiology, vascular, and cardiothoracic services across Michigan. This collaboration of cardiovascular physicians and surgeons should expand the services and therapies across McLaren’s health system while increasing access to technology and research. The initiative follows the system’s foray into advanced procedures like TAVR, Watchman, T-CAR, and WEB.
- Surgeons Support Digital Tech: Medtronic’s State of Surgery report highlighted a budding confidence in digital health tools as a way to close the gap in surgical expertise for underserved communities. Of the 1k surgeons surveyed, 84% see potential in telemedicine for remote consultations, while 82% believe live streaming procedures could improve outcomes through real-time knowledge sharing. Over 4 in 5 surgeons are also looking to level the educational playing field using new tech like VR, digital training platforms, and cloud-based patient records.
- Teleprehab Pre-surgery:JACC brought another example of how digital health solutions are making their way into the physical world of cardiac surgery. A new study showed that teleprehabilitation—pre-surgery patient training to boost mental and physical fitness to reduce adverse perioperative outcomes—can reduce MACE in elective cardiac surgery patients. In 394 patients, those receiving teleprehab had fewer MACE events (16.8% vs. 25.5%), while teleprehab also improved smoking and depression, but didn’t shorten hospital stays.
|
|
New Horizons in Structural Heart
TAVR and TMVR rates are rising rapidly, placing more pressure on interventional planning. Tune into this Circle CVI and Radcliffe Cardiology breakout detailing how to leverage modern CT workflows to produce efficient and accurate pre-procedural plans.
|
|
Forging the Future of Cardiovascular Care
Cardiology is changing, and for the better. Get a view into Lee Health Heart Institute’s medical director Richard Chazal, MD’s vision for a new era in cardiology, driven by imaging, AI and personalized medicine.
|
|
Discover Innovation in Intervention
Explore how the AGENT™ Drug-Coated Balloon from Boston Scientific is advancing U.S.-based treatment options for patients with coronary artery disease. Rx Only. (Sponsored by Boston Scientific)
|
|
- Innovating AFib Care: The first manifestation of AFib is often stroke, but many hospitals aren’t set up to coordinate these patients’ post-stroke care. See how UCSD is leveraging Viz.ai’s Viz Connect solution to simplify neuro and EP collaboration in this HRX 2024 interview.
- Monebo’s AF ECG Algorithm: Atrial fibrillation is often difficult to characterize with an automated algorithm due to the changing waveform morphology, system, or muscle noise. This is especially true given the size constraints of ambulatory devices to detect AFib. See how Monebo’s Kinetic AF ECG Algorithm overcomes these size limitations without sacrificing accuracy.
- Experience the future of learning: Medtronic Academy 2.0 is here! Unlock your ultimate destination for structural heart medical education with the newly redesigned Medtronic Academy 2.0. Gain access to expert-led courses, webinars, and a wealth of resources to stay ahead in cardiovascular care. Visit now!
- Structured Reporting, Redefined: Ready to realize the benefits of cardiovascular imaging structured reporting? See how Optum’s structured reporting could completely change how clinicians use data, while streamlining the imaging reimbursement process and making it easier to communicate.
- HeartFlow FFRCT Avoids Invasive Cath: Despite being conscious about his heart health, 60-year old Mike Gartman suddenly experienced classic symptoms of CAD. See how Mike’s HeartFlow FFRCT Analysis results allowed him to avoid the invasive procedure altogether and gain peace of mind about his disease.
- Relieving The Burden of Post-Processing: With the advent of advanced imaging technologies like CCTA come added burdens to technologists and diagnostic imaging centers. See how PIA can relieve the burden of post-processing, saving you time while helping your bottom line.
- A Solution for Your Entire Cardiology Service Line: The pace of change in healthcare can be dizzying, creating new and more complex challenges for cardiology departments to overcome. See how Merge Cardio and Merge Hemo can turn those challenges into opportunities for greater workflow efficiency and improved care.
|
|
|
|
|
